*****
Summary of Transcript:
The Drive podcast host, Dr. Peter Attia, and his guest, Matt Caberlon, discuss aging biomarkers and molecular compounds believed to be protective against aging, including NAD, rapamycin, and metformin. They aim to provide a comprehensive understanding of the current state of research on the three molecules and their potential as anti-aging agents. They also touch on biomarkers of aging and their limitations in predicting future health outcomes. They are joined by Nick, who compiles questions from subscribers to explore these topics further.
*****
Summary of Description:
Peter Attia and Dr. Matt Kaeberlein discuss aging biomarkers, epigenetic clocks, and three molecules – NAD, metformin, and rapamycin – and their geroprotective qualities in this episode of The Peter Attia Drive podcast. They compare data from NAD precursors like nicotinamide riboside and nicotinamide mononucleotide to studies on metformin and rapamycin, assessing how they stack against each other and discussing how to make sense of experimental data and approach future research. The episode also covers the advantages and limitations of studying aging in non-humans, the strengths and weaknesses of different model systems, the importance of control lifespans, and the problems with reproducibility in aging studies.
*****
Have you ever wondered about the secrets to increasing lifespan and improving healthspan? The Peter Attia Drive podcast is a great place to start, with its weekly deep dives into fasting, ketosis, Alzheimer’s disease, cancer, and mental health. In this episode, Peter is joined by Dr. Matt Kaeberlein to discuss the field of aging, focusing on three molecules with purported geroprotective qualities: NAD, metformin, and rapamycin.
Peter and Dr. Kaeberlein discuss aging biomarkers and epigenetic clocks before delving into the advantages and limitations of the most common experimental models for studying aging and pharmacological possibilities for extending lifespan. They then deep dive into NAD and its precursors, nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), comparing data from NAD precursors to studies on metformin and rapamycin. Through this comparison, they illustrate how to make sense of new experimental data and how to make intelligent decisions about future research.
In this sneak peek, they discuss the logic behind comparing NAD precursors to rapamycin and metformin, aging biomarkers, and epigenetic clocks. The whole episode also explores the advantages and limitations of studying aging in non-humans, the importance of controlling lifespans, and the problems with reproducibility. Peter and Dr. Kaeberlein also introduce NAD, its potential roles in aging, and its relationship to sirtuins.
They discuss human studies with NAD precursors, the concept of “clean drugs” versus “dirty drugs,” the lack of rapamycin studies in humans compared to NAD and metformin, and the ranking of geroprotective molecules in terms of risk and reward. With over 40 million episodes downloaded, this episode of The Peter Attia Drive is worth a listen for anyone interested in maximizing health and longevity.
*****
Source Description
Become a member to watch this whole episode: https://bit.ly/37MLc4J
See episode show notes here: https://bit.ly/3Lcz3Ul
Sign up to receive Peter’s email newsletter: https://bit.ly/3l8y0KJ
In this “Ask Me Anything” (AMA) episode, Peter is joined by special guest Dr. Matt Kaeberlein. Together they answer many questions about the field of aging with an emphasis on three specific molecules—NAD, metformin, and rapamycin—and their purported geroprotective qualities. They first discuss aging biomarkers and epigenetic clocks before breaking down the advantages and limitations of the most common experimental models used today to study aging and pharmacological possibilities for extending lifespan. Next, they dive deep into NAD and the much-hyped NAD precursors, nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). They compare data from NAD precursors to studies on metformin and rapamycin, assessing how they stack up against each other and using the comparison to illustrate how to make sense of new experimental data and make intelligent decisions about how to approach future research.
In this sneak peek, we discuss the following:
00:00 – Logic behind comparing NAD precursors to rapamycin and metformin;
03:49 – Aging biomarkers: current state, usefulness, and future promise;
12:37 – Epigenetic clocks: definition, use case, and limitations;
In the entire episode, we also discuss the following:
– Advantages and limitations of studying aging in non-humans and the strengths and weaknesses of different model systems;
– Aging studies: the importance of control lifespans and the problems with reproducibility;
– Intro to NAD, potential role in aging, relationship to sirtuins, and more;
– NAD precursors (NR and NMN): current data;
– Human studies with NAD precursors;
– Comparing NAD lifespan data to data from metformin and rapamycin;
– Defining a “clean drug” and a “dirty drug”;
– Reason for the lack of rapamycin studies in humans compared to NAD and metformin;
– Ranking the neuroprotective molecules in terms of risk and reward; and
– More.
——–
About:
The Peter Attia Drive is a weekly, ultra-deep-dive podcast focusing on maximizing health, longevity, critical thinking…and a few other things. With over 40 million episodes downloaded, it features topics including fasting, ketosis, Alzheimer’s disease, cancer, mental health, and much more.
Peter is a physician focusing on the applied science of longevity. His practice extensively deals with nutritional interventions, exercise physiology, sleep physiology, emotional and mental health, and pharmacology to increase lifespan (delay the onset of chronic disease) while improving healthspan (quality of life).
Learn more: https://bit.ly/3Mg5zGz.
Connect with Peter on:
Facebook: http://bit.ly/PeterAttiaMDFB
Twitter: http://bit.ly/PeterAttiaMDTW
Instagram: http://bit.ly/PeterAttiaMDIG
Subscribe to The Drive:
Apple Podcast: http://bit.ly/TheDriveApplePodcasts
Overcast: http://bit.ly/TheDriveOvercast
Spotify: http://bit.ly/TheDriveSpotify
Google Podcasts: http://bit.ly/TheDriveGoogle
Comments are closed